Influence of diuretic therapy on the features of heart rhythm variability changes in chronic heart failure patients

Abstract

Aim. To study comparative influence of furosemide and torasemide on heart rhythm variability in patients with chronic heart failure of ischemic origin.

Methods. The study included 48 patients (29 males and 19 females) with ischemic heart disease complicated by chronic heart failure, NYHA functional classes II-IV. All patients were randomized into two groups: group 1 (25 patients) received furosemide as diuretic therapy, and group 2 (23 patients) received torasemide. All patient underwent clinical examination including assessment of complaints and physical examination, laboratory and instrumental tests (electrocardiography, echocardiography, 6-minute walk test, 24 Hour Holter ECG monitoring) before and 30 days after starting diuretic therapy.

Results. Against the background of one-month diuretic therapy, positive dynamics of clinical parameters was registered in both main groups of patients receiving both furosemide and torasemide. In furosemide group deterioration of heart rhythm variability was observed. Torasemide treatment resulted in considerable improvement of vegetative regulation of heart activity.

Conclusion. Diuretic therapy with furosemide is characterized by changes of time and spectral parameters of vegetative regulation of heart rhythm towards strengthening of sympathetic and attenuation of parasympathetic influence; diuretic therapy with torasemide resulted in considerable improvement of heart rhythm variability parameters, attenuation of sympathetic and strengthening of parasympathetic influence on heart rhythm that provides additional cardioprotection in the treatment of patients with chronic heart failure of ischemic origin.

Keywords

chronic heart failure / diuretics / furosemide / torasemide / heart rhythm variability

References

[1] Shugushev Kh.Kh., Gaeva A.A. Effect of furosemide and torasemide on heart rate variability and ventricular rhythm disorders in patients with chronic heart failure complicating ischemic heart disease: comparative nonrandomized research. Ratsional’naya Farmakoterapiya v Kardiologii. 2010; 6 (4): 513–517. (In Russ.)

[2] Шугушев Х.Х., Гаева А.А. Влияние фуросемида и торасемида на ВРС и желудочковые аритмии у больных с хронической сердечной недостаточностью, осложнившей течение ишемической болезни сердца: сравнительное нерандомизированное исследование. Рациональн. фармакотерап. в кардиол. 2010; 6 (4): 513-517.

[3] Sidorenko B.A., Preobrazhenskiy D.V., Batyraliev T.A. The place of diuretics in the treatment of chronic heart failure. Part I. Kardiologiya. 2005; 45 (8): 76–83. (In Russ.)

[4] Сидоренко Б.А., Преображенский Д.В., Батыралиев Т.А. Место диуретиков в лечении хронической сердечной недостаточности. Часть I. Кардиология. 2005; 45 (8): 76-83.

[5] Zagravskaya I.A. Cardiac arrhythmias and electrolytic imbalance blood with a relatively chronic heart failure loop diuretic. Rossiyskiy mediko-biologicheskiy vestnik im. akademika I.P. Pavlova. 2010; (2): 78–85. (In Russ.)

[6] Загравская И.А. Нарушения ритма сердца и электролитный дисбаланс крови при сравнительном лечении хронической сердечной недостаточности петлевыми диуретиками. Рос. мед.-биол. вестн. им. акад. И.П. Павлова. 2010; (2): 78-85.

[7] Cody R.J., Cubo S.H., Pikworth K.K. Diuretic treatment for the sodium retention of congestive heart failure. Arch. Intern. Med. 1994; 154: 1905–1914. DOI: 10.1001/archinte.1994.00420170045004.

[8] Cody R.J., Cubo S.H., Pikworth K.K. Diuretic treatment for the sodium retention of congestive heart failure. Arch. Intern. Med. 1994; 154: 1905-1914. DOI: 10.1001/archinte.1994.00420170045004.

[9] Patterson J.R., Adams K.F., Applefeld M.M. et al. Torasemide Investigators Group. Oral torasemide in patients with chroinic heart failure: effects on body weight, edema and electrolyte excretion. Pharmacotherapy. 1994; 14: 514–521. DOI: 10.1002/j.1875-9114.1994.tb02848.x.

[10] Patterson J.R., Adams K.F., Applefeld M.M. et al. Torasemide Investigators Group. Oral torasemide in patients with chroinic heart failure: effects on body weight, edema and electrolyte excretion. Pharmacotherapy. 1994; 14: 514-521. DOI: 10.1002/j.1875-9114.1994.tb02848.x.

[11] Couper H.A., Dries D.I., Davis C.E. et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999; 100: 1311–1315. DOI: 10.1161/01.CIR.100.12.1311.

[12] Couper H.A., Dries D.I., Davis C.E. et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999; 100: 1311-1315. DOI: 10.1161/01.CIR.100.12.1311.

[13] Brater D.C. Torasemide: pharmacokinetic and-clinical efficacy. Eur. J. Heart Failure. 2001; 3 (Suppl. G): 19–24. DOI: 10.1016/S0195-668X(01)80004-X.

[14] Brater D.C. Torasemide: pharmacokinetic and-clinical efficacy. Eur. J. Heart Failure. 2001; 3 (Suppl. G): 19-24. DOI: 10.1016/S0195-668X(01)80004-X.

[15] Tomiyama H., Nakayama Т., Watanabe G. et al. Effekt of short-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Am. Heart J. 1999; 137 (3): 543–548. DOI: 10.1016/S0002-8703(99)70504-1.

[16] Tomiyama H., Nakayama Т., Watanabe G. et al. Effekt of short-acting loop diuretics on heart rate variability in patients with chronic compensated congestive heart failure. Am. Heart J. 1999; 137 (3): 543-548. DOI: 10.1016/S0002-8703(99)70504-1.

[17] Muller K., Gamba G., Jaquet F., Hess B. Torasemid vs. furosemid in-primary care patients with chronic heart failure NYHA II to IV — efficacy and quality of life. Eur. J. Heart Failure. 2003; 5 (6): 793–801. DOI: 10.1016/S1388-9842(03)00150-8.

[18] Muller K., Gamba G., Jaquet F., Hess B. Torasemid vs. furosemid in-primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur. J. Heart Failure. 2003; 5 (6): 793-801. DOI: 10.1016/S1388-9842(03)00150-8.

[19] Yamato M., Sasaki T., Honda K. et al. Effects of torasemide in left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003; 67 (5): 384–390. DOI: 10.1253/circj.67.384.

[20] Yamato M., Sasaki T., Honda K. et al. Effects of torasemide in left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003; 67 (5): 384-390. DOI: 10.1253/circj.67.384.

[21] Murray M., Deep M., Ferguson J. et al. Open-label randomized trial of torasemide compared with furosemide therapy for-patients with heart failure. Am. J. Med. 2001; 111 (7): 513–520. DOI: 10.1016/S0002-9343(01)00903-2.

[22] Murray M., Deep M., Ferguson J. et al. Open-label randomized trial of torasemide compared with furosemide therapy for-patients with heart failure. Am. J. Med. 2001; 111 (7): 513-520. DOI: 10.1016/S0002-9343(01)00903-2.

[23] Cosin J., Diez J. TORIC investigators. Torasemid in chronic hear failure results of the TORIC study. Eur. J. Heart Failure. 2002; 4 (4): 507–513. DOI: 10.1016/S1388-9842(02)00122-8.

[24] Cosin J., Diez J. TORIC investigators. Torasemid in chronic hear failure results of the TORIC study. Eur. J. Heart Failure. 2002; 4 (4): 507-513. DOI: 10.1016/S1388-9842(02)00122-8.

[25] Kasama S., Tiyana Т., Hatori Т. et al. Effect of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart. 2006; 92 (10): 1434–1440. DOI: 10.1136/hrt.2005.079764.

[26] Kasama S., Tiyana Т., Hatori Т. et al. Effect of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart. 2006; 92 (10): 1434-1440. DOI: 10.1136/hrt.2005.079764.

[27] Mentz R.J., Buggey J., Fiuzat M. et al. Torasemide versus furosemide in heart failure patients: insights from Duke University Hospital. J. Cardiovasc. Pharmacol. 2015; 65 (5): 438–443. DOI: 10.1097/FJC.0000000000000212.

[28] Mentz R.J., Buggey J., Fiuzat M. et al. Torasemide versus furosemide in heart failure patients: insights from Duke University Hospital. J. Cardiovasc. Pharmacol. 2015; 65 (5): 438-443. DOI: 10.1097/FJC.0000000000000212.

[29] Baevskiy R.M., Ivanov G.G. Analysis of heart rate variability of various ECG systems. Methodical guidelines. Vestnik aritmologii. 2001; (24): 65–86. (In Russ.)

[30] Баевский P.M., Иванов Г.Г. Анализ вариабельности сердечного ритма при использовании различных электрокардиографических систем. Методические рекомендации. Вестн. аритмол. 2001; (24): 65-86.

[31] Standarts of measurement, physiological inter­pretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur. Heart J. 1996; 17: 354–381.

[32] Standarts of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur. Heart J. 1996; 17: 354-381.

RIGHTS & PERMISSIONS

Alyeva K.R., Bakhshaliev A.B., Kakhramanova S.M.